📰 Label Extension Study News
Label Extension Study News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Label Extension Study. Real-time updates on events, politics, business and more.
February 15, 2024
John W. Day, MD, PhD, Professor of Neurology and Pediatrics, and Director, Division of Neuromuscular Medicine, Stanford University School of Medicine and a principal investigator in END-DM1,...
July 25, 2023
– Totality of data from these ongoing studies suggest clinical benefit for patients ages 2 to 18 years old, including reductions in seizures and improvements in cognition and behavior that support the potential for disease modification –– Phase 1/2a ADMIRAL Study Data STK-001 (70mg): Patients treated with 2 or 3 ini...
April 27, 2023
Interim 2-year findings show soticlestat appeared generally safe and well tolerated, consistent with prior studiesSustained reduction in frequency of drop...
April 27, 2023
Interim 2-year findings show soticlestat appeared generally safe and well tolerated, consistent with prior studiesSustained reduction in frequency of drop seizures among Lennox-Gastaut patients and... | June 18, 2023
February 21, 2023
/PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced additional positive interim data from a Phase 2 open-label extension (OLE) study of...
August 10, 2022
/PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative...
August 10, 2022
/PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative...
May 12, 2022
/PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative...
May 12, 2022
Press release content from Globe Newswire. The AP news staff was not involved in its creation.